OLA then crossover to DEX for Chemotherapy-induced Nausea and Vomiting

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Chemotherapy-induced Nausea and VomitingDEX group: Dexamethasone - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this research is to compare two drugs that are routinely used as standard of care for treating nausea and vomiting caused by chemotherapy. This study aims to see if the drug olanzapine is as good as the steroid drug dexamethasone for preventing nausea and vomiting after chemotherapy. Both drugs are listed as appropriate treatment options in the most recent version of National Comprehensive Cancer Network guidelines on Antiemesis.

Eligible Conditions
  • Chemotherapy-induced Nausea and Vomiting

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 120 hours after chemotherapy

120 hours after chemotherapy
Nausea
Severity of nausea and vomiting self-reported by patient questionnaire
Pharmaceutical Preparations
120 hours following chemotherapy
Complete control (CC- no emesis, no rescue medication and no more than minimal nausea)
Pharmacotherapy
Nausea

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

DEX then crossover to OLA
1 of 2
OLA then crossover to DEX
1 of 2

Active Control

Experimental Treatment

104 Total Participants · 2 Treatment Groups

Primary Treatment: OLA then crossover to DEX · No Placebo Group · Phase 4

OLA then crossover to DEXExperimental Group · 2 Interventions: DEX group: Dexamethasone, OLA group: Olanzapine · Intervention Types: Drug, Drug
DEX then crossover to OLAActiveComparator Group · 2 Interventions: DEX group: Dexamethasone, OLA group: Olanzapine · Intervention Types: Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 120 hours after chemotherapy

Who is running the clinical trial?

The Guthrie ClinicLead Sponsor
23 Previous Clinical Trials
1,945 Total Patients Enrolled
Nicole Ink, PharmDPrincipal InvestigatorThe Guthrie Clinic

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: